BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 2436132)

  • 1. [Contribution of anthracyclines in treatment of lymphoproliferative disorders].
    Coiffier B
    Pathol Biol (Paris); 1987 Jan; 35(1):75-8. PubMed ID: 2436132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
    Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV].
    Lopez M
    Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542
    [No Abstract]   [Full Text] [Related]  

  • 6. Pediatric Hodgkin's disease.
    Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
    J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Diehl V; Fuchs M;
    Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
    Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
    Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
    J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hodgkin's lymphoma--the great teacher.
    Connors JM
    N Engl J Med; 2011 Jul; 365(3):264-5. PubMed ID: 21774715
    [No Abstract]   [Full Text] [Related]  

  • 11. Greater curability in advanced Hodgkin's disease?
    Portlock CS
    Cancer J Sci Am; 1999; 5(5):264-5. PubMed ID: 10526665
    [No Abstract]   [Full Text] [Related]  

  • 12. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease.
    Raina V; Sharma A; Mohanti BK; Kumar R; Dawar R; Rath GK
    Natl Med J India; 2003; 16(4):199-203. PubMed ID: 14606767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
    Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
    J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-line salvage chemotherapy in Hodgkin's disease.
    Bonadonna G; Viviani S; Valagussa P; Bonfante V; Santoro A
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):23-5. PubMed ID: 2579440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Protocols for the treatment of leukemia and lymphoma: toward escalation or toward reduction of degree?].
    Mathé G; Misset JL; Machover D; Schwarzenberg L; Timus M; Jasmin C; Ribaud P; Musset M
    Biomed Pharmacother; 1984; 38(1):13-32. PubMed ID: 6380605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
    Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
    Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM; Colonna P
    J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
    [No Abstract]   [Full Text] [Related]  

  • 19. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
    J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.